The Food and Drug Administration approved Wegovy HD on March 24, a new 7.2 mg formulation of semaglutide — the GLP-1 receptor agonist that is the active ingredient in the obesity drug Wegovy — that is triple the previous maximum approved dose of 2.4 mg. The drug, manufactured by Danish pharmaceutical company Novo Nordisk, was approved for adults with obesity or overweight conditions accompanied by weight-related comorbidities such as high blood pressure, type 2 diabetes, or cardiovascular disease. It is the fourth drug approved under the FDA's National Priority Voucher pilot program, designed to accelerate review of treatments for high-burden conditions. Fox News health coverage confirmed the approval under the headline "Greater weight loss promised by higher-dose Wegovy shot, now approved by FDA."
Clinical trial data submitted to the FDA showed patients receiving the 7.2 mg dose experienced an average weight loss of approximately 20.7%, compared to roughly 16% for patients on the standard 2.4 mg dose. About one-third of participants in the higher-dose trial lost 25% or more of their body weight — a threshold that obesity medicine specialists consider meaningful for patients with severe obesity. Novo Nordisk executive vice president Jamey Millar stated that no other weight-loss medication has demonstrated superiority to Wegovy HD in clinical studies. The drug approval is specifically for obesity management, not diabetes treatment, and the company cautioned against using it as a substitute for semaglutide formulations approved for type 2 diabetes.
Dr. Peter Balazs, a hormone and weight-loss specialist who was not involved in the trial, told Fox News: "For patients who start on 2.4 mg and then hit a frustrating plateau, this creates a legitimate, evidence-based escalation path rather than forcing an early switch to another drug class." He noted that the higher dosage represents a "major jump" with "meaningful" gastrointestinal and skin-related side effects. Common adverse effects at the higher dose include nausea, vomiting, diarrhea, constipation, and abdominal pain — the same profile as lower-dose semaglutide but more frequently reported. Skin sensitivity, pain, and burning also occurred more often at 7.2 mg but generally resolved on their own or with dose adjustment.
The approval carries significant implications for the obesity drug market, which has grown explosively since semaglutide's initial approval. Insurers and Medicare have been grappling with coverage decisions as GLP-1 drugs have demonstrated benefits beyond weight loss, including reductions in cardiovascular events and, in some studies, improvements in kidney function and sleep apnea. The higher-dose approval is expected to prompt renewed debate over whether Medicare should cover the drug at its higher cost tier — Wegovy currently costs approximately $1,300 per month without insurance — and whether the increased weight-loss efficacy justifies broader coverage mandates. The FDA is continuing to investigate some adverse effects associated with the higher dose.
Left-Leaning Emphasis
- Left-leaning and health policy coverage focused on the insurance and Medicare coverage implications, noting that the higher-dose approval will intensify pressure on payers to cover GLP-1 drugs more broadly at a time when the federal government is simultaneously pursuing Medicaid cost reductions — creating a tension between evidence-based obesity treatment and budget constraints.
- Progressive health advocates noted that at approximately $1,300 per month without insurance, Wegovy HD remains inaccessible to most low-income Americans who bear the highest burden of obesity-related disease, arguing the approval underscores the need for drug pricing reform alongside FDA action.
Right-Leaning Emphasis
- Fox News and right-leaning coverage framed the Wegovy HD approval as a triumph of pharmaceutical innovation under the FDA's expedited review programs, citing the drug's efficacy data as evidence that the free market and fast-track approval processes are delivering life-changing results for patients with obesity.
- Conservative health commentators noted that the approval came under the Trump FDA, characterizing it as an example of the administration cutting regulatory red tape to speed life-saving treatments to market — contrasting it with what they described as slower approval timelines under prior administrations.